← ANALYST RATINGS · TIPRANKS
Liquidia Technologies (LQDA): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy2 Hold0 Sell
Ratings of 8 analysts in the last 3 months12-month forecast
Based on 8 price targets given in the last 3 months, the average target is $53.12, the highest $70.00, the lowest $33.00. The average is +54.7% from the last price of $34.35.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $58.00 → $65.00+12.1% | Buy | +89.2% | Reiterated | 15.10.26on TipRanks 06:20 | +2.2%next day −0.1% | ↗ |
| AI xAi Medical - PharmaceuticalsxAI Grok-3 | TipRanks - xAI | $29.00 → $38.00+31.0% | Buy | +10.6% | Upgrade | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek Medical - PharmaceuticalsDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $29.00 → $38.00+31.0% | Buy | +10.6% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI Medical - PharmaceuticalsOpenAI 5.2 | TipRanks - OpenAI | $28.00 → $36.00+28.6% | Hold | +4.8% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic Medical - PharmaceuticalsAnthropic Opus-4.6 | TipRanks - Anthropic | $27.00 → $35.00+29.6% | Hold | +1.9% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Google Medical - PharmaceuticalsGemini 3-pro | TipRanks - Google | $29.00 → $37.00+27.6% | Hold | +7.7% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity Medical - PharmaceuticalsPerPlexity SonarPro | TipRanks - PerPlexity | $29.00 → $36.00+24.1% | Hold | +4.8% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $38.00 → $42.00+10.5% | Hold | +22.3% | Reiterated | 14.10.26on TipRanks Oct 15 05:30 | +27.7%next day +2.2% | ↗ |
| Gaurav Maini★★★★★★★★★★#2199 · hits 88% · avg +29.5% | LifeSci Capital | $90.00 → $59.00−34.4% | Buy | +71.8% | Upgrade | 14.10.26on TipRanks 07:40 | +27.7%next day +2.2% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $72.00 → $58.00−19.4% | Buy | +68.9% | Reiterated | 14.10.26on TipRanks 07:30 | +27.7%next day +2.2% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $111 → $70.00−36.9% | Buy | +103.8% | Upgrade | 14.10.26on TipRanks 06:10 | +27.7%next day +2.2% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $30.00 → $33.00+10.0% | Hold | −3.9% | Reiterated | 13.10.26on TipRanks Oct 14 05:50 | −3.1%next day +27.7% | ↗ |
| Amy Li★★★★★★★★★★#5687 · hits 36% · avg +7.6% | Jefferies | $45.00 | Buy | +31.0% | Reiterated | 05.10.26on TipRanks 09:55 | −4.2%next day −6.8% · 5 days −0.3% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | $106 → $53.00−50.0% | Buy | +54.3% | Reiterated | 30.09.26on TipRanks 14:15 | −57.0%next day −7.7% · 5 days −13.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Liquidia Technologies
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $81.20 at a price of $30.26 (+168.3%); now: $53.12 at $34.35 (+54.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 0 | 1 | 2 | 5 | 12 |
| Buy | 14 | 16 | 17 | 13 | 8 | 5 |
| Hold | 1 | 2 | 2 | 3 | 3 | 9 |
| Sell | 1 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.92 (from $0.66 to $1.24). Last quarter: $0.74.
Sales
Next quarter’s sales estimate — $214M (from $181M to $226M). Last quarter: $172M.
Best top-analyst consensus in the sector · Healthcare
About Liquidia Technologies
- CEO: Roger A. Jeffs
- Employees: 216
- 419 Davis Drive, Morrisville, NC, 27560, US
- www.liquidia.com
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Data from the stock’s TipRanks forecast page, read 7 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗